Abramson Cancer Center at Penn Medicine: Carcinoma, Renal Cell trials

The registry lists 10 Carcinoma, Renal Cell studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 2 are open to participants now and 1 have results posted.

Early Phase 1 2Phase 1 3Phase 2 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)RecruitingNCT06770855Not applicable
• Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingNCT05733715Early Phase 1
• Brivanib Metastatic Renal Cell CarcinomaTerminatedNCT01253668Phase 2Results posted
• Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1
• CRLX101 Plus Bevacizumab in Advanced RCCCompletedNCT01625936Phase 1
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
• Cardiovascular Effects of Sunitinib Therapy (CREST)CompletedNCT01370109
• Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)CompletedNCT01221506Early Phase 1
• Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney CancerCompletedNCT01026337
• Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney CancerStatus unknownNCT00717587Phase 2